Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas

Fig. 4

OS and PFS rates according to the expression of DKK3, CSNK1A1, FSTL1, and CTNNB1 in patients with grade II or III glioma and GBM. (A) Kaplan–Meier curves showing the OS and PFS rates according to DKK3 tertiles in WHO grade II or III glioma; (B) Kaplan–Meier curves showing the OS and PFS rates according to DKK3 tertiles in WHO grade IV GBM; (C) Kaplan–Meier curves showing the OS and PFS rates according to FSTL1 tertiles in WHO grade II or III glioma; (D) Kaplan–Meier curves showing the OS and PFS rates according to FSTL1 tertiles in WHO grade IV GBM; (E) Kaplan–Meier curves showing the OS and PFS rates according to CSNK1A1 tertiles in WHO grade II or III glioma; (F) Kaplan–Meier curves showing the OS and PFS rates according to CSNK1A1 tertiles in WHO grade IV GBM; (G) Kaplan–Meier curves showing the OS and PFS rates according to CTNNB1 tertiles in WHO grade II or III glioma; (H) Kaplan–Meier curves showing the OS and PFS rates according to CTNNB1 tertiles in WHO grade IV GBM.

CSNK1A1, casein kinase 1 alpha 1; CTNNB1, catenin beta 1; DKK3, dickkopf WNT signaling pathway inhibitor 3; FSTL1, follistatin-like 1; GBM, glioblastoma multiforme; OS, overall survival; PFS, progression-free survival

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us